To determine whether more progressed skin tumors also regress upon the C/EBPβ deletion, we conducted another DMBA/TPA tumor study where mice were treated with tamoxifen at 34 weeks of TPA treatment (compared with 19 weeks in the previous experiment). The gene discussed is CEBPB; the disease is skin neoplasm.